CSL Limited
Australian multinational specialty biotechnology company researching, developing, manufacturing, and marketing products to treat serious human medical conditions, including blood plasma derivatives, vaccines, antivenom, and cell culture reagents.
相关临床试验
32
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1994
进行中（未招募）
18
56.3%
已完成
14
43.8%
暂无批准数据
- The European Medicines Agency has recommended pulling marketing authorization for Tavneos, citing unreliable efficacy data and good clinical practice concerns in the pivotal study. - The European Commission has opened an antitrust investigation into Sanofi's flu vaccine campaign, alleging misleading promotion that criticized CSL Seqirus's Fluad in France and Germany. - CSL shares closed at A$114.87 on Friday, down 2.36%, with the Tavneos news landing after ASX trading closed, leaving the stock yet to price in the regulatory setback. - CSL had already lowered FY26 guidance in May to approximately $15.2 billion revenue and $3.1 billion NPATA, with around $5 billion in additional non-cash impairments expected across FY26 and FY27.
- The global vaccine adjuvants market was valued at USD 4.00 billion in 2025 and is projected to reach USD 6.19 billion by 2035, growing at a CAGR of 4.47%. - The U.S. market alone is expected to expand from USD 0.62 billion in 2025 to USD 1.61 billion by 2035, reflecting a robust CAGR of 9.05%. - Oncology vaccines represent the fastest-growing application segment, fueled by investments in cancer immunotherapy, personalized vaccines, and neoantigen-based therapies. - Combination adjuvants and intradermal administration are poised for the most rapid growth, while GSK and Novavax continue advancing next-generation adjuvant platforms.
- India's Supreme Court will rule on whether the Competition Commission of India (CCI) has jurisdiction to investigate anti-competitive conduct arising from patent rights exercise, following conflicting tribunal decisions. - The case centers on pharmaceutical company Vifor International AG's patented drug Ferric Carboxymaltose (FCM), where the National Company Law Appellate Tribunal ruled the CCI lacks jurisdiction over patent-related competition disputes. - The Supreme Court has stayed portions of the NCLAT ruling that held the Patents Act, 1970 overrides the Competition Act, 2002 in matters involving patent rights abuse. - The decision will significantly impact pharmaceutical and technology companies' patent strategies and market operations in India, particularly regarding licensing practices and competition law compliance.
- CSL Seqirus has opened a state-of-the-art $1 billion cell-based influenza vaccine and antivenom manufacturing facility in Melbourne, making Australia one of only three countries globally with end-to-end cell-based flu vaccine capabilities. - The facility is the only cell-based influenza vaccine manufacturing site in the Southern Hemisphere and the world's only facility capable of producing Australia's eleven antivenoms for venomous creatures plus the human Q-Fever vaccine. - The new facility can produce over 150 million pandemic vaccines in the first wave of manufacturing and supports a $300 million annual supply chain to the Australian economy. - The facility replaces CSL Seqirus' 80-year-old egg-based vaccine manufacturing operation in Parkville, Melbourne, representing a major technological advancement in vaccine production capabilities.
